Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a report released on Monday. The firm set a “sell” rating on the stock.

Bio-Path Price Performance

Shares of NASDAQ:BPTH opened at $0.18 on Monday. The stock’s 50-day simple moving average is $0.64 and its two-hundred day simple moving average is $0.84. Bio-Path has a 52-week low of $0.12 and a 52-week high of $7.67.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.